Context The benefit of surgical metastasectomy (SM) for patients with metastatic renal cell
carcinoma (mRCC) remains controversial because of the lack of high-level evidence on the …

Purpose Metastatic renal cell carcinoma (mRCC) still harbours a big propensity for future
metastasis. Combinations of immune and targeted therapies are currently the cornerstone of …

Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common kidney tumor. If
feasible, metastasectomy is preferably indicated in metastatic disease. Objective: The aim of …

Background Treatment landscape for advanced renal cell carcinoma (aRCC) has evolved
quickly and few data about the real-world treatment patterns are available. This study aimed …

Objective The aim of this study was to predict the discriminating prognostic power of the
neutrophil-to-lymphocyte ratio for overall survival in patients with metastatic renal cell …

Background Two main therapies, pazopanib and sunitinib, are used in the first-line setting
for metastatic renal cell carcinoma (mRCC). These two tyrosine kinase inhibitors (TKI) are …

Background Targeted therapies have transformed the treatment of metastatic clear-cell renal
cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic …

Lacking high-level evidences, the benefit of cytoreductive treatments in patients with
metastatic renal cell carcinoma remains controversial. To investigate advantages and …

Background The introduction of novel systemic therapies for metastatic renal cell carcinoma
(mRCC) over the last decade has significantly improved patient outcomes. Little information …

Résumé Cet article est une revue de la littérature qui a pour objectif de clarifier la place des
traitements systémiques et des traitements locorégionaux, en particulier la radiothérapie et …